Related Experiment Videos
Chemotherapy dosing in the setting of liver dysfunction
John W Eklund1, Steve Trifilio, Mary F Mulcahy
1Hematology/Oncology Fellow, Department of Medicine, Division of Hematology-Oncology, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois 60611, USA.
Oncology (Williston Park, N.Y.)
|September 1, 2005
Summary
Chemotherapy dosing for advanced cancer with liver dysfunction requires careful consideration. Some agents are safer, while others pose significant risks, necessitating cautious management and further research for clear guidelines.
Area of Science:
- Oncology
- Hepatology
- Pharmacology
Background:
- Advanced cancer with liver dysfunction presents a significant clinical challenge.
- Many chemotherapy drugs are metabolized by the liver, complicating treatment in patients with hepatic impairment.
- Cytotoxic agents often have a narrow therapeutic index, increasing safety concerns in patients with liver dysfunction.
Purpose of the Study:
- To review cancer chemotherapy dosing strategies in patients with liver dysfunction.
- To identify chemotherapy agents with varying safety profiles in the context of hepatic impairment.
- To highlight the need for evidence-based dosing guidelines for cancer treatment in liver dysfunction.
Main Methods:
- A concise review of existing literature on cancer chemotherapy dosing in liver dysfunction.
- Analysis of the metabolic pathways and safety data of various chemotherapeutic agents.
- Identification of agents with relatively better or worse tolerability in hepatic impairment.
Main Results:
- Continuous-infusion fluorouracil, capecitabine, mechlorethamine, cyclophosphamide, topotecan, and oxaliplatin appear relatively well tolerated.
- Taxanes, vinca alkaloids, irinotecan, and anthracyclines may lead to unacceptable toxicity in patients with poor liver function.
- Limited data exists for many anticancer agents, hindering formal dosing recommendations.
Conclusions:
- Caution is essential when administering chemotherapy to patients with liver dysfunction.
- Specific chemotherapy agents demonstrate differential safety profiles in hepatic impairment.
- Further research is needed to establish evidence-based dosing guidelines for cancer chemotherapy in liver dysfunction.